micro-community-banner
 
  • Saved

1yr
American Society of Clinical Oncology Annual Meeting 2024

The American Society of Clinical Oncology (ASCO) will host its annual meeting in Chicago and online from May 31 to June 4, 2024. The theme of this year’s conference is The Art and Science of Cancer Care: From Comfort to Cure.

  • Saved

1yr
Romidepsin Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Versus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Final Analysis of the Ro-CHOP Trial

Romidepsin Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Versus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Final Analysis of the Ro-CHOP Trial

Source : https://pubmed.ncbi.nlm.nih.gov/38364196/

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or...

Within the limits of highly heterogeneous second-line treatments, no specific regimen seemed to provide superior disease control.

  • Saved

1yr

Ponatinib vs Imatinib in Frontline Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia: a Randomized Clinical Trial

Source : https://jamanetwork.com/journals/jama/fullarticle/2818574

Ponatinib demonstrated a superior rate of minimal residual disease–negative complete remission at the end of induction versus imatinib when combined with reduced-intensity chemotherapy.

  • Saved

1yr
Comparison of Comorbidity Models Within a Population-Based Cohort of Older Adults With Non-Hodgkin Lymphoma

Comparison of Comorbidity Models Within a Population-Based Cohort of Older Adults With Non-Hodgkin Lymphoma

Source : https://pubmed.ncbi.nlm.nih.gov/38684043/

The optimal measure of comorbidity in NHL is unknown. Here, we demonstrate that the three-category TRES and five-category NHL-5 scores perform as well as the 14-16 category CCI and NCI...

Researchers found similar associations with OS and lymphoma-specific survival, which was confirmed in sensitivity analyses by non-Hodgkin lymphoma subtypes.

  • Saved

1yr
Clonal Hematopoiesis and Therapy-Related Myeloid Neoplasms After Autologous Transplant for Hodgkin Lymphoma

Clonal Hematopoiesis and Therapy-Related Myeloid Neoplasms After Autologous Transplant for Hodgkin Lymphoma

Source : https://pubmed.ncbi.nlm.nih.gov/38635938/

The presence of TP53 and/or PPM1D mutations in the PBSC product increases the risk of post-aPBSCT t-MN and nonrelapse mortality among patients with HL and may support alternative therapeutic strategies.

All patients with TP53 mutations in the peripheral blood stem cell transplantation product developed therapy-related myeloid neoplasm, whereas none of the patients with DNMT3A mutations alone did.